Publications

Ganti AKP, Loo BW, Badiyan S, Bassetti M, Bestvina C, Chiang A, Choudhury N, D'Avella CA, Daly M, Dowlati A, Edelman M, Florsheim C, Gold KA, Goldman JW, Grecula JC, Hann C, Khalil M, Lee R, Malhotra J, Merritt RE, Mohindra N, Molina JR, Moran C, Mulvey C, Osmundson EC, Patel S, Patil T, Pokharel S, Puri S, Qin A, Sands J, Shields M, Tailor TD, Waqar SN, Cassara CJ, Ramakrishnan S. NCCN Guidelines® Insights: Small Cell Lung Cancer, Version 2.2026. Journal of the National Comprehensive Cancer Network : JNCCN. 2026. PMID: 41671459

Pasricha ND, Kim SK, Farooq AV, Lindgren ES, Yan R, Seitzman GD, Chan MF, Shantha JG, Skondra D, Jeng BH, Chamberlain WD, Colby KA, Goldstein DA, Sobrin L, Kim IK, Singh K, Chambers WA, Boyd WM, Silverstein J, Pohlmann PR, Lu J, Glencer AC, Huppert LA, Chien AJ, Rugo HS, Esserman LJ. Multicenter Interspecialty Consensus on Experimental Oncology Drug-Related Ocular Adverse Event Reporting. JAMA ophthalmology. 2026. PMID: 41343206

McKay RR, Pal S, Xie W, Aggen D, Albiges L, Apolo A, Atkins MB, Bangs R, Beckermann KE, Bellmunt J, Berg SA, Bilen MA, Braun D, Carlo MI, Efstathiou J, Galsky M, Grivas P, Gupta S, Haas N, Hakimi AA, Hammers H, Heng DYC, Hirsch M, Iyer G, Jonasch E, Koshkin VS, Kryvenko O, Lewis B, Li R, Matin S, Maughan B, McDermott DF, McGregor B, Meeks J, Milowsky M, Motzer R, Necchi A, Petrylak D, Porten S, Powles T, Rini B, Shuch B, Siefker-Radtke A, Sonpavde G, Sridhar SS, Suarez C, Tang C, Tripathi A, Van Der Heijden MS, Voss M, Xu W, Zhang T, Rosenberg J, Choueiri TK. Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers. CA: a cancer journal for clinicians. 2026. PMID: 41389316

Martin TG, Mateos MV, Yi JH, van de Donk NWCJ, Cai Z, Fu W, Garfall AL, Iida S, Jung SH, Kuroda Y, Niu T, Nooka AK, Min CK, Sidana S, Chastain K, Doyle M, Nishikawa K, Wang X, Song Y, Yamazaki H, Izumi Y, Zhuo J, Zhu A, Yoon DH, Du J, Ishida T. Efficacy and safety of teclistamab in triple-class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort. Cancer. 2026. PMID: 41485109

Pasricha ND, Kim SK, Farooq AV, Lindgren ES, Yan R, Seitzman GD, Chan MF, Shantha JG, Skondra D, Jeng BH, Chamberlain WD, Colby KA, Goldstein DA, Sobrin L, Kim IK, Singh K, Chambers WA, Boyd WM, Silverstein J, Pohlmann PR, Lu J, Glencer AC, Huppert LA, Chien AJ, Rugo HS, Esserman LJ. Multicenter Interspecialty Consensus on Experimental Oncology Drug-Related Ocular Adverse Event Reporting. JAMA ophthalmology. 2026. PMID: 41343206

Gebrael G, Agarwal N, Morgans AK, Vince R, Swami U, Jia AY, Zaorsky N, Chehade CH, Ozay ZI, Malone S, Morgan SC, Wallis CJD, Kishan AU, Barata PC, Chowdhury S, Garcia JA, Sheng I, Brown JR, Small EJ, Sun Y, Shore ND, Saad F, Spratt DE, Roy S. Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials. Cancer. 2026. PMID: 41420831

Gou X, Chen H, Diolaiti ME, Ashworth A. Identification of a Two-Gene Biomarker Correlated with Sensitivity to Combined PARP7 Inhibition and AHR Activation in Cancer Cells. Cancer Research Communications. 2026. PMID: 41295982

Saj F, Namayanja FK, Xiao L, Borad MJ, Kelley RK, Goyal L, Azad NS, Bachini M, Lindsey S, Pant S, Valle JW, Fashoyin-Aje LA, Javle M. Broadening the gates: Analysis of potentially modifiable study entry criteria in pancreatic and biliary tract cancer trials. Cancer. 2026. PMID: 41417596

Alban J, Bowen RC, Reichstein DA, McKean M, Lutzky J, Weis E, Carvajal RD, Dulka S, Morse BG, Butler MO, Rapisuwon S, Kim KB, Chandrasekaran S, Warner AB, Zager JS, Chmielowski B, Patel SP, Hernandez-Aya LF, Correa ZM, Fecher LA, Najjar YG, Montazeri K, Shoushtari AN, Javed A, Gombos DS, Salama AKS, Tsai K, Miller FH, Khushalani N, Seedor RS, Lipson EJ, Reddy SA, Buchbinder E, Bhatia S, Pavlick A, Mehmi I, Aaberg T, Ikeguchi AP, Kim IK, Walter SD, Singh AD, Sullivan RJ, Choi JS, Williams BK, Orloff M, Mruthyunjaya P, Schollenberger MD, Gandhi N, Harbour JW, Chandra S. Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus. Cancers. 2025. PMID: 41514630

Kim J, Correy GJ, Hall BW, Rachman MM, Mailhot O, Togo T, Gonciarz RL, Jaishankar P, Neitz RJ, Hantz ER, Doruk YU, Stevens MGV, Diolaiti ME, Reid R, Gopalkrishnan S, Krogan NJ, Renslo AR, Ashworth A, Shoichet BK, Fraser JS. Large scale prospective evaluation of co-folding across 557 Mac1-ligand complexes and three virtual screens. bioRxiv : the preprint server for biology. 2025. PMID: 41509292

Park YH, Cortes J, Modi S, Hurvitz SA, Bianchini G, Iwata H, Shitara K, Siena S, Goto Y, Ku GY, Powell CA, Swain SM, Arunachalam M, Janek M, Cheng Y, Chu C, Verma P, Kuptsova-Clarkson N, Mathias E, Goodman E, Rugo HS. Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studies. The oncologist. 2025. PMID: 41330717

Seo L, Farran I, Aslam A, Li X, Jaishankar P, Ashworth A, Fraser JS, Renslo AR, Wankowicz SA. Crystallographic Ensembles Reveal the Structural Basis of Binding Entropy in SARS-CoV2 Macrodomain. bioRxiv : the preprint server for biology. 2025. PMID: 41394572

Trepka KR, Van Blarigan EL, Kyaw TS, Olson CA, Partipilo G, Ortega EF, Noecker C, Upadhyay V, Zhang C, Gempis D, Steiding P, Stanfield D, Venook AP, Atreya CE, Kidder WA, Turnbaugh PJ. Shifts in the human gut microbiome during cancer chemotherapy are diet-dependent. bioRxiv : the preprint server for biology. 2025. PMID: 41497648

Trepka KR, Van Blarigan EL, Kyaw TS, Olson CA, Partipilo G, Ortega EF, Noecker C, Upadhyay V, Zhang C, Gempis D, Steiding P, Stanfield D, Venook AP, Atreya CE, Kidder WA, Turnbaugh PJ. Shifts in the human gut microbiome during cancer chemotherapy are diet-dependent. bioRxiv : the preprint server for biology. 2025. PMID: 41497648

Pistilli B, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Tsurutani J, Kalinsky K, Rubini Liedke PE, Carroll D, Khan S, Rugo HS, Xu B, Bardia A, TROPION-Breast01 investigators. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study. Annals of oncology : official journal of the European Society for Medical Oncology. 2025. PMID: 41448362

Trepka KR, Van Blarigan EL, Kyaw TS, Olson CA, Partipilo G, Ortega EF, Noecker C, Upadhyay V, Zhang C, Gempis D, Steiding P, Stanfield D, Venook AP, Atreya CE, Kidder WA, Turnbaugh PJ. Shifts in the human gut microbiome during cancer chemotherapy are diet-dependent. bioRxiv : the preprint server for biology. 2025. PMID: 41497648

Ashouri K, Millstein J, Yang Y, Xiu J, Soni S, Mittal P, Algaze S, Torres-Gonzalez L, Jayachandran P, Zhang W, Mumenthaler S, Shields AF, Goldberg R, Lou E, Weinberg BA, Graeber TG, Marshall JL, Venook AP, Hoffmann A, Finley SD, Meyer AS, Battaglin F, Lenz HJ. Clinical and molecular characterization of AXL in colorectal cancer, CALGB (Alliance)/SWOG 80405 and real-world data. Journal for immunotherapy of cancer. 2025. PMID: 41423272

Tawagi K, Khaki AR, Chablani PV, Hoffman-Censits J, Koshkin VS, Plimack ER, Galsky MD, Gupta S, Rosenberg JE, Grivas P, O'Donnell PH. Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary Oncologists. Clinical genitourinary cancer. 2025. PMID: 41582039

Chan SL, Kudo M, Sangro B, Kelley RK, Kim JH, Pham B, Hong JY, Waldschmidt DT, Marino D, Joycelyn Lee JX, Gerolami R, Burgoyne AM, Li Q, Nakamura H, Sun P, Baur B, Rimassa L. Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis. Liver cancer. 2025. PMID: 41585428

Jaishankar P, Correy GJ, Matsui Y, Togo T, Rachman MM, Stevens MGV, Hantz ER, Zheng J, Diolaiti ME, Montano M, Taha TY, Rosecrans J, Pampel J, Krogan NJ, Shoichet BK, Ashworth A, Ott M, Fraser JS, Renslo AR. Discovery of AVI-6451, a Potent and Selective Inhibitor of the SARS-CoV-2 ADP-Ribosylhydrolase Mac1 with Oral Efficacy In Vivo. Journal of medicinal chemistry. 2025. PMID: 41406955